Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks details its Earnings ESP (Expected Surprise Prediction), which compares the Most Accurate Estimate to the Zacks Consensus and—when paired with a Zacks Rank #3 or better—historically produced positive surprises 70% of the time and a 28.3% average annual return in a 10-year backtest. Centene (CNC) is a Zacks #3 with a Most Accurate EPS of $1.98 versus a $1.95 consensus (ESP +1.52%) ahead of its July 26, 2024 report; Eli Lilly (LLY) shows a Most Accurate EPS of $2.82 versus a $2.65 consensus (ESP +6.49%) ahead of its August 13, 2024 release. The article promotes using the ESP filter to identify names with a higher probability of beating or missing expectations for short-term earnings trades.

Analysis

Market structure: Positive Earnings ESP (CNC +1.52% on July 26, LLY +6.49% on Aug 13) concentrates short-term flows into healthcare/medical names and options buys. Winners: managed-care/large-cap biopharma equities and analysts who revise estimates; losers: pre-earnings option sellers and crowded long names that miss. A beat will likely compress insurer credit spreads (basis points) and lift defensive healthcare relative to cyclicals for weeks.

Risk assessment: Immediate (days) — elevated IV and drift, with a historical ~70% hit-rate for Zacks filters but small ESP like CNC is noisy; short-term (weeks/months) — guidance and enrollment/pipeline updates matter; long-term (quarters/years) — regulatory (drug pricing, Medicaid pass-throughs) and patent/pipeline risks can wipe 20–40% of market cap. Tail risks: sudden Medicare/Medicaid policy shifts, major trial failures for LLY, or state-level rate actions for CNC within 30–180 days.

Trade implications: Use defined-risk option structures to capture asymmetric payoffs: for CNC favor a 2–3% portfolio notional buy of a 1–2 month call spread entered 7–14 days pre-earnings (cap upside, limit IV decay); for LLY prefer directional Sep calls or buying post-announcement on confirmed beat to avoid IV crush. Pair trade: long CNC vs short HUM (or crowded managed-care ETF) to isolate operational outperformance; rotate 1–3% from cyclicals into healthcare on confirmed beats.

Contrarian angles: The market overweights ESP as a binary signal — +1.52% is marginal and likely priced quickly; +6.49% for LLY is meaningful and may already be baked into IV (expect >5–10% move priced). Historical parallels: earnings-beat rallies often fade if management guidance is conservative; unintended consequence — crowded ESP longs can create sharp reversals when guidance disappoints, so size and defined-risk matter.

Key Decisions for Investors

• Establish a 2–3% portfolio notional long position in CNC ahead of July 26 via a 1–2 month ATM call spread (buy ATM, sell 10–15% OTM) entered 7–14 days pre-earnings; target 8–15% stock upside, stop-loss: 40% premium loss.
• Allocate 1–2% notional to LLY but avoid expensive pre-earnings straddles: buy Sep 2024 calls (near-the-money to 5% OTM) after Aug 13 if a beat and guidance is neutral/positive; if you prefer pre-event, size to 0.5–1% only.
• Initiate a relative-value pair trade: long CNC / short HUM equal-dollar exposure (1–2% net each) around CNC earnings to capture operational beat skew; unwind within 5–15 trading days post-release or on divergence >10% between names.
• Monitor regulatory and enrollment triggers: reduce CNC exposure by 50% if state Medicaid capitation guidance or enrollment miss appears within 30–90 days; reduce LLY by 50% on any FDA negative label/pipeline news or major pricing-policy hearings flagged within 60–180 days.